KLOW is a combination of four peptides that has been freeze-dried and is present in a 10 ml multi-use vial. The nomenclature of this compound follows that of GLOW, as P in this case represents "Peace" or the peptide KPV, with the remaining components being the same as those of GLOW.
In the research field, each peptide in KLOW refers to its own primary activity mechanism, which allows applying this combination in multiple protocols dealing with tissue healing, skin treatment, and inflammation. The total quantity of peptides is 80 mg and is distributed among four different peptides. The blue color observed in the vial is due to the presence of GHK-Cu, the copper-binding peptide, and has nothing to do with contamination.
| Peptide | Primary Research Role | mg in 80 mg Vial | Route Emphasis |
|---|---|---|---|
| BPC-157 | Gut lining repair, tendon and ligament healing, angiogenesis. | 20 mg. | Subcutaneous / oral. |
| TB-500 | Systemic tissue repair, actin regulation, inflammation modulation. | 20 mg. | Subcutaneous. |
| GHK-Cu | Collagen synthesis, wound healing, skin remodeling. | 20 mg. | Subcutaneous / topical. |
| KPV (Lys-Pro-Val) | NF-kB inhibition, cytokine suppression, gut epithelial anti-inflammatory via PepT1. | 20 mg. | Oral (gut) / subcutaneous (systemic). |
<p style="font-family: 'Arial', sans-serif; font-size: 14px; color: #1a1a1a; margin: 20px 0; line-height: 1.6;">
At a <span style="color: #1a1a1a; font-weight: 600;">1:1:1:1 ratio</span>, each peptide contributes equally by mass. In practice, this is a sound formulation choice rather than a clinically proven one - no trials have ever tested this combination in humans. Some gut-targeted protocols stack KLOW with a separate oral KPV capsule to raise the gut-local dose without changing injection volume, but US Peptide Labs does not list a separate KPV SKU online.
</p>
The KLOW vial contains 80 mg total lyophilized powder in 10 mL after it is reconstituted. By using 2 mL bacteriostatic water, each 10 units of an insulin syringe, delivers 0.4 mg of the blend and 0.1 mg of each peptide. The published protocols on use of individual peptides use higher-doses, which is the reason that KLOW is often termed as a maintenance or combined-target protocol rather than a high-dose of peptide therapy.
| Reconstitution Volume | Syringe Units | Total Blend / Dose | KPV / Dose | BPC-157 / Dose | TB-500 / Dose | GHK-Cu / Dose |
|---|---|---|---|---|---|---|
| 2 mL BW | 10 units. | 0.4 mg. | 0.1 mg (100 mcg). | 0.1 mg (100 mcg). | 0.1 mg (100 mcg). | 0.1 mg (100 mcg). |
| 2 mL BW | 20 units. | 0.8 mg. | 0.2 mg (200 mcg). | 0.2 mg (200 mcg). | 0.2 mg (200 mcg). | 0.2 mg (200 mcg). |
| 2 mL BW | 25 units. | 1.0 mg. | 0.25 mg (250 mcg). | 0.25 mg (250 mcg). | 0.25 mg (250 mcg). | 0.25 mg (250 mcg). |
| 1 mL BW | 10 units. | 0.8 mg. | 0.2 mg (200 mcg). | 0.2 mg (200 mcg). | 0.2 mg (200 mcg). | 0.2 mg (200 mcg). |
Protocols applied for conducting independent studies on KPV peptide recommend dosages ranging from 200-500 mcg in the subcutaneous form for once a day intake while studying the effects of the organic compound on the gut. During the preparation of KLOW, equal to 20-25 units mixed with the solvent equals 2 mL of liquid, KPV falls within the lower subcutaneous dosage range. Scientists focused on achieving results regarding the condition of the distal gut may sometimes apply both forms of KPV: the oral one and the injected KLOW.
In terms of published animal models frequency will be once a day, continuous. Cycle length in research protocols consists of 4-8 weeks, which is in line with the individual peptides in the blend. Use the peptide dosage calculator to calculate vial math for different reconstitution volumes and dosage targets. A complete guide is available on the KLOW dosage chart site.
In clinical research protocols, KLOW is given just once per day, each time in the morning, before the time of feeding. The timing of the morning administration is consistent with the study protocols of BPC-157 and TB-500, as published. The short complexity of KPV – measured in minutes up to one hour according to its tripeptide nature – means that it matters less when in time KPV is administered because the key is regularity and consistency rather than the timing.
In subcutaneous research protocols, the abdomen is the chosen area for injection. In specific protocols related to Dermatology, KPV injection is made at the site of the skin affected, particularly in psoriasis or a wound model. GHK-Cu injection has the highest number of local reactions out of all the components of the combination.
Making the solution: using a syringe, slowly inject 1-2 mL of bacteriostatic water into each vial while aiming for the glass wall of the vial. Do not shake. Store reconstituted vials in the 2-8 degrees C range (standard refrigerator temperatures) in a light-protected environment. Unreconstituted lyophilized powder should be stored cool and dry.
Duration of cycles: 6-8 weeks is the average timeframe for development. It is customary in animal studies to allow for a rest period prior to commencing another cycle. However, it is unclear how long the rest period should last before using the blend again on volunteers. The peptide dosage calculator contains information on the conversion of units of any volume for reconstitution.
Out of the four peptides offered by KLOW, the most commonly reported negative effect is irritation at the injection site, of which GHK-Cu is the most probable cause due to its copper composition and the tissue reactions of copper chelates. Proper dilution - with a reconstitution volume of 2 mL instead of the usual 1 mL - can alleviate this side effect. Researchers have registered mild fatigue during the first week, which corresponds with the reported effects of BPC-157 and TB-500.
Repeatedly asked two questions regarding KPV peptide: possible liver toxicity and cancer risk. The answer for both questions is the same: there was no liver signal and no cancer signal in KPV literature. KPV has non-growth-promoting properties, and it does not initiate growth hormone or IGF-1 pathways, which causes concerns about GH-related peptides. The non-existence of signals does not mean safety; it is just that there are no mechanisms to be concerned about in this particular tripeptide.
The important point regarding KLOW is that there has been no published study that has investigated these four peptides together. While each peptide has its own data on safety in animals, there is no safety data on their combination. There are no long-term data in human subjects to support the use of any of these peptides alone or together. Researchers should document their observations carefully when using KLOW and treat it appropriately as a novel research formulation.
The four peptides used in KLOW - BPC-157, TB-500, GHK-Cu, or KPV - are not licensed drugs by FDA. In 2026, the pertinent legal question concerning US researchers is whether any of the peptides may be compounded by a pharmacy for human usage. The response for all of them is negative.
According to Section 503A, compounding pharmacies can only use various drug substances as indicated at FDA's finalized 503A bulks list. Unfortunately, KPV is not included among those items. Likewise, 503B outsourcing facility bulks list does not mention KPV, TB-500, BPC-157, or GHK-Cu so none of the KLOW Peptides have been granted an approved compounding pathway (through either 503A or 503B facilities).
As stated by US Peptide Labs, KLOW may be used for research purposes only, and it is not meant to be considered as a drug, medicine, or any compounded drug. It is not intended for human use and can only be sold to researchers aged 21 years or older.
TB-500 is straightforwardly listed as prohibited. For example, in the 2026 WADA Prohibited List under S2.3 text, it is stated that "Thymosin-beta-4 and its derivatives, TB-500, are prohibited". Consequently, KLOW is prohibited for every athlete being tested under WADA rules because it contains TB-500.
The substances KPV, BPC-157, and GHK-Cu are not presently included in the WADA prohibited list for 2021. However, the position may be altered as WADA revises its list every year. It is advisable for athletes participating in regulated sports to assume that any TG-500-containing multi-peptide solution is banned regardless of its other ingredients.
In making a choice between blends, its depends on whether the research objective is inflammatory and gut-focused, recovery-focused, or skin-focused. In contrast, KLOW enhances the GLOW foundation with the inclusion of KPV anti-inflammatory and gut layer.
| Product | Peptides | Primary Research Target | KPV Included | TB-500 Included (WADA) |
|---|---|---|---|---|
| KLOW | BPC-157, TB-500, GHK-Cu, KPV. | Repair + gut + inflammation + skin. | Yes. | Yes. |
| GLOW | BPC-157, TB-500, GHK-Cu. | Repair + skin + recovery. | No. | Yes. |
| Wolverine (BPC-157 / TB-500) | BPC-157, TB-500. | Musculoskeletal repair, healing. | No. | Yes. |
| GHK-Cu Alone | GHK-Cu. | Skin remodeling, collagen. | No. | No. |
| BPC-157 Alone | BPC-157. | Gut repair, tendon healing. | No. | No. |
Researchers focused primarily on gut inflammation or mast-cell-associated models should note that KLOW is the sole blend available that contains KPV. If your interest lies with musculoskeletal protocols, TB-500 standalone or the BPC-157/TB-500-blend may suit your needs better. For gut-related work and to avoid any WADA concerns regarding TB-500, BPC-157 alone, or alternately KPV delivered orally when it becomes available as a separate SKU, are good options. Find out more in the complete peptides for gut healing guide.
KLOW fits research endeavors requiring simultaneous examination of more than one system. So, if the research issue is narrow, the design of the four-peptide fusion may not be optimal.
Research into skin and recovery: KLOW accounts for the GHK-Cu collagen and wound-healing process, the TB-500 systemic recovery process, and BPC-157’s angiogenic and recovery effects in a single vial. The inclusion of KPV adds anti-inflammatory action both locally in the injection site and systemically. Researchers investigating skin inflammation and wound models with inflammation may refer to the scientific rationale behind this combination. If skin remodeling takes place without recovery peptides only, using GHK-Cu alone is obviously easier. Detailed information can be found on the website indicated above.
The research of KPV in the field of gut and inflammation is one of the areas where it marks a significant difference from the existing products. Although BPC-157 has its own scientific findings in the field of gut recovery, the combination of its properties with the mucosal anti-inflammatory action of KPV works as the rationale for a two-component project in the gut treatment which might be effective. Several researchers carry out discussions about mechanisms that enable such functionality, which makes this combination of the two peptides even more appealing.
KLOW blend is available at US Peptide Labs comes in a 10 mL lyophilized vial with a total of 80 mg (20 mg of each component, BPC–157, TB–500, GHK–Cu, and KPV). Price is $145.00 per vial with bulk pricing at $137.75 for the purchase of 2 and $130.50 on the purchase of 5. Free shipping in the United States is available on orders above $70 and purchase implies confirmation of being older than 21 years.
At this moment, the US Peptide Labs inventory does not carry a standalone KPV 10mg SKU. The only product available in the inventory is KLOW which contains KPV peptide. Hence, researchers who are interested in oral only gut protocols or individuals who need a higher dose of KPV than what the blend provides should keep this limitation in mind.
U.S. Peptide Labs’ “lab tested” indicates that a specific independent COA is available upon request, reflecting the lot number that can be found printed at the bottom of the vial. Given that the peptides are made in the U.S.A. laboratory, we have provided a comprehensive information resource on how to read a COA for those inquiries of new researchers, since that is the most frequently asked query by them as to the purity statistics provided on any 3rd party lab report. In brief, high-pressure liquid chromatography (HPLC) purity must exceed 98% while mass spectrometry should confirm the correct molecular mass of the substance and be provided by an independent lab (not a paper prepared at some internal laboratory). The COA page at US Peptide Labs contains the documents pertaining to the present lot.
Other products that you can compare available in the store are the full healing and recovery collection. TB-500 10 mg is sold at $80.0. BPC-157 10 mg costs $65.0. You can order the BPC-157/TB-500 blend at a price of $85.0. Also available is GHK-Cu 50 mg at a cost of $60.0.
KLOW is composed of four peptides in equal parts of 20 mg each. The four peptides are BPC-157 (body protection compound which aids in tissue and gut healing), TB-500 (thymosin beta-4 fragment, which helps in systemic healing), GHK-Cu (copper tripeptide which acts on skin and collagen), and KPV (lysine-proline-valine that has an anti-inflammatory role and heals the gut lining). Overall content equals 80 mg in a lyophilized vial of 10 mL. The blue color present in the reconstituted vial is due to the copper chelate of GHK-Cu, as anticipated.
According to the research protocols, KLOW is given only once daily during the morning period. The blend of KLOW is prepared by adding 2 ml of bacteriostatic water and 20 units on an insulin syringe so that the final preparation contains 0.8 mg (0.2 mg/200 mcg of each of the peptide). The research cycle lasts for about 6-8 weeks. Please refer to dosage calculator to get the information about the number of units for the required dose as well as the volume of the reconstitution.
The abdomen is the preferred site of subcutaneous injection in studies involving the four peptides in the formulation. The normal injection technique for KPV-specific dermatological models in the literature reportedly involves the injection near the target lesion for targeted treatment. Alternate injection sites can lessen irritation on the injection site, especially with GHK-Cu. If sufficient dilution is performed (i.e., reconstitution with 2 ml instead of 1 ml), the incidence of injection site reactions can be minimized.
The variables of interest in the study involve using GLOW, which contains BPC-157, TB-500, and GHK-Cu, versus the KLOW formulation, which adds KPV to provide the added benefits of inhibiting NF-kB, suppressing a variety of cytokines (including IL-6, TNF-alpha, IL-1beta), and providing PepT1 mediated anti-inflammatory support in gut epithelial tissues. Therefore, depending on the research protocol, one may consider using KLOW formulation if either gut inflammation or inflammation signaling is a variable being tested. In contrast, when working purely with skin and repair related activities omitting inflammation and gut, GLOW is better suited as it uses the same three peptides with a possibility of a higher dose of each peptide per injection.
None of the four peptides in KLOW (namely, BPC-157, TB-500, GHK-Cu, and KPV) are approved medications by the FDA or mentioned in 503A and 503B compounding bulks lists. KLOW is offered as a research-use-only product by the US Peptide Labs and cannot be used for treating, diagnosing, or curing human beings. To buy the product, US scientists must be older than 21 years old.
Injection-site irritation appears to be the most common side effect across four different types of peptides. GHK-Cu is often considered to be responsible for this irritation, which could be minimized if the peptide is diluted properly so it remains harmless. In addition to that, there are some reports about mild fatigue during the initial week of using the peptides. However, there are no signs of toxicity for KPV in the liver or any signals indicating cancer in the available literature. KPV does not stimulate growth as it is a small fragment and does not activate the GH or IGF-1 pathways. The use of all four peptides together has not been tested in any study, so there is no data on their combined safety. No evidence exists regarding safety of all four peptides when used in humans.
View the KLOW Blend at US Peptide Labs - 80 mg, Lot-Specific COA, Free US Shipping from $70